Dan Wildman, in addition to being a Board member, is a Strategic Advisor to PanTher Therapeutics. In this role Dan applies his expertise and decades of experience to advancing the clinical development program for PanTher’s lead program, PTM-101, and selecting and prioritizing other Sagittari™ platform product candidates. A seasoned executive with more than 35 years of experience in the MedTech industry, Dan is President of Wildman Ventures, LLC. He also currently serves as a member of the Board of Directors or as a Strategic Advisor for several early-stage organizations and publicly-held companies.
Prior to joining PanTher Therapeutics, Dan led the Digital Surgery Strategy initiative at Johnson & Johnson and served as worldwide President of Depuy Synthes Spine, the second-largest spine surgery business in the world. Previously, he served as Worldwide President of Ethicon Biosurgery, where he led the development and commercialization of a novel combination product based on a biomaterial and biologic formulation. The biosurgery business at Ethicon now exceeds $2.0B in revenue and continues to be one of the fastest-growing companies in Johnson & Johnson’s medical device portfolio.